Zentalis Pharmaceuticals
ZNTL
145 hedge funds and large institutions have $314M invested in Zentalis Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 56 increasing their positions, 42 reducing their positions, and 21 closing their positions.
446% more call options, than puts
Call options by funds: $262K | Put options by funds: $48K
33% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 42
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
2% more funds holding
Funds holding: 142 → 145 (+3)
12.23% less ownership
Funds ownership: 120.2% → 107.96% (-12%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
77% less capital invested
Capital invested by funds: $1.34B → $314M (-$1.03B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14M |
| 2 |
DC
Decheng Capital
Menlo Park,
California
|
+$10.8M |
| 3 |
Morgan Stanley
New York
|
+$10.2M |
| 4 |
Two Sigma Investments
New York
|
+$9.02M |
| 5 |
Two Sigma Advisers
New York
|
+$7.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$33.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28.7M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$23.9M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$22.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$22M |
ZNTL Hedge Fund Activity: Q2 2024 in Review
145 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q2 2024, worth a combined $314M — down 77% from $1.34B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ZNTL positions and 21 closed out — a net gain of 5 holders — while 56 added to existing stakes and 42 trimmed.
The largest buyer was Vanguard Group, adding an estimated $14M. The largest seller was Eventide Asset Management, cutting an estimated $33.8M.
- 145 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q2 2024, up from 142 in Q1 2024.
- Funds reported $314M of Zentalis Pharmaceuticals stock for Q2 2024, down 77% quarter-over-quarter.
- 26 funds opened new Zentalis Pharmaceuticals positions in Q2 2024 and 21 closed out, a net change of +5 holders.
- The largest Zentalis Pharmaceuticals buyer in Q2 2024 was Vanguard Group, an estimated $14M added.
- The largest Zentalis Pharmaceuticals seller in Q2 2024 was Eventide Asset Management, an estimated $33.8M sold.
Based on aggregated 13F filings for Q2 2024.